It has been reported that the median half-life of an antibody–cytokine fusion protein, hu14.18-IL-2, which has been used for the treatment of refractory or recurrent neuroblastoma and melanoma, was only 3.1 h in clinical application.211 Therefore, the half-life of the fusion protein and its therapeutic effect were disappointing. The gene discussed is IL2; the disease is melanoma.